Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma

Intern Med J. 2017 Sep;47(9):1086-1088. doi: 10.1111/imj.13538.

Authors

Ida Orlando¹, Antonio Vitale¹, Donato Rigante², Giuseppe Lopalco³, Claudia Fabiani⁴, Luca Cantarini¹

Affiliations

¹ Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.
² Institute of Pediatrics, Catholic University of the Sacred Heart, A. Gemelli Hospital, Rome, Italy.
³ Interdisciplinary Department of Medicine, Rheumatology Unit, Bari, Italy.
⁴ Department of Ophthalmology, Humanitas Clinical and Research Center, Milan, Italy.

PMID: 28891187
DOI: 10.1111/imj.13538

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / administration & dosage*
Behcet Syndrome / complications
Behcet Syndrome / drug therapy*
Behcet Syndrome / physiopathology
Carcinoma, Papillary / drug therapy*
Drug Therapy, Combination
Humans
Interleukin 1 Receptor Antagonist Protein / administration & dosage*
Interleukin-1 / antagonists & inhibitors*
Male
Middle Aged
Treatment Outcome
Uveitis / drug therapy*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Interleukin 1 Receptor Antagonist Protein
Interleukin-1
canakinumab